Figure 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
Year: 2026
Type: other
Abstract: Patient disposition. aThree patients were discontinued from treatment (all due to death) before the first postbaseline scan and did not have response data available. bData cutoff: February 25, 2025. cTwo patients discontinued pembrolizumab only due to AEs.
Authors: Paul L. Swiecicki, Glenn J. Hanna, Jessica L. Geiger, Takao Fujisawa, Missak Haigentz, Yoshitaka Honma, Justine Y. Bruce, Kaoru Tanaka, Kei Muro, Priyanka Bhateja, Jason Kaplan, Shubin Liu, Seema Gorla, Michele Wozniak, Ryan Dillon, Salaheldin Hamed, Changting Meng, Marya F. Chaney, Ari J. Rosenberg
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7203476372
Cites:
Cited by:
Related to: